By Allison Sit The FDA has approved Olumiant (baricitinib) as a first-in-disease systemic treatment for adults with severe alopecia areata. Olumniant is a once-daily, oral JAK inhibitor. "People with alopecia…
Read More
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.